Previous studies have shown that homologous recombination-deficient tumor cells resulting from BRCA1 or BRCA2 gene mutations are hypersensitive to the inhibitory effect of poly-ADP ribose polymerase-1 (PARP-1) (Lin & Kraus, 2017; McCann, 2019). This evidence concerns the gene PARP1 and neoplasm.